Fibrocell receives FDA regenerative medicine advanced therapy designation for FCX-007 gene therapy for the treatment of RDEB

29 May 2019 - Fibrocell Science today announced that the U.S. FDA has granted the regenerative medicine advanced therapy designation to ...

Read more →

Bayer receives U.S. FDA breakthrough therapy designation for copanlisib for the treatment of marginal zone lymphoma

29 May 2019 - Breakthrough therapy designation for copanlisib primarily based on follow-up data from the pivotal Phase II study ...

Read more →

Zymeworks' lead asset, ZW25, granted fast track designation from the FDA

29 May 2019 - Zymeworks today announced that the U.S. FDA has granted fast track designation to ZW25, a novel azymetric ...

Read more →

Arvinas receives fast track designation for its targeted protein degrader ARV-110 as a treatment for men with metastatic castration-resistant prostate cancer

29 May 2019 - Arvinas today announced that its lead Protac protein degrader, ARV-110, has been granted fast track designation by ...

Read more →

Imara announces FDA fast track designation for IMR-687 for the treatment of sickle cell disease

29 May 2019 - Imara today announced that the U.S. FDA has granted fast track designation to IMR-687, the company’s ...

Read more →

Health Canada approves Tecentriq (atezolizumab) combination therapy for first-line treatment of metastatic non-squamous non-small cell lung cancer

29 May 2019 - Data show this new option can help some patients with metastatic non-small cell lung cancer live significantly ...

Read more →

Janssen announces Health Canada approval of Tremfya One-Press (guselkumab) - a patient-controlled injector for adults with moderate-to-severe plaque psoriasis

29 May 2019 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that Health Canada has approved Tremfya One-Press, ...

Read more →

FDA officials call for patient-friendly terminology in oncology

29 May 2019 - Officials from the US FDA's oncology offices say they plan to develop a glossary of patient-friendly ...

Read more →

Health advocate says FDA must walk a 'fine line' to ensure affordable drugs are safe

29 May 2019 - Public health advocate Dinesh Thakur said in an interview that aired Wednesday that the FDA is ...

Read more →

U.S. FDA grants priority review for Vascepa (icosapent ethyl) supplemental new drug application seeking cardiovascular risk reduction indication

29 May 2019 - PDUFA date assigned is 28 September 2019, four months sooner than expected. ...

Read more →

Highlights from the CHMP 27-29 May 2019 meeting

29 May 2019 - EMA’s CHMP recommended four medicines for approval at its May 2019 meeting. ...

Read more →

European Medicines Agency accepts marketing authorisation application for Prestige BioPharma’s trastuzumab biosimilar HD201 for review

28 May 2019 - Prestige BioPharma  announced that EMA has validated and accepted for review the marketing authorisation application for ...

Read more →

FDA approves Revlimid (lenalidomide) in combination with rituximab for the treatment of adult patients with previously treated follicular lymphoma or marginal zone lymphoma

28 May 2019 - Approval marks the first chemotherapy-free combination regimen for patients who have relapsed or did not respond to ...

Read more →

Sermonix receives FDA fast track designation for investigational drug lasofoxifene

28 May 2019 - Designation allows for expedited development and review of lasofoxifene as a potential precision medicine treatment for women ...

Read more →

Assessment of the clinical benefit of cancer drugs receiving accelerated approval

28 May 2019 - When a cancer drug that has received accelerated approval from the US FDA is claimed to have ...

Read more →